Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development
Tongqi Qian, Naoto Fujiwara, Bhuvaneswari Koneru, et al.
Gastroenterology (2021) Vol. 162, Iss. 4, pp. 1210-1225
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Current and future colorectal cancer screening strategies
Aasma Shaukat, Theodore R. Levin
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 8, pp. 521-531
Open Access | Times Cited: 294
Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases
Maja Thiele, Ida Falk Villesen, Lili Niu, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 2, pp. 345-359
Open Access | Times Cited: 16
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease
Naoto Fujiwara, Naoto Kubota, Émilie Crouchet, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 650
Open Access | Times Cited: 67
Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines
Lijun Gong, Fang Wei, Frank J. Gonzalez, et al.
Hepatology (2023) Vol. 78, Iss. 5, pp. 1625-1653
Open Access | Times Cited: 18
CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis
Xin Song, Chensheng Jiang, Mengli Yu, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 8, pp. 1597-1605
Closed Access | Times Cited: 6
Macrophage metabolism in nonalcoholic fatty liver disease
Wenhui Zhang, Ren Lang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Targeting Hepatic Stellate Cells for the Prevention and Treatment of Liver Cirrhosis and Hepatocellular Carcinoma: Strategies and Clinical Translation
Hao Xiong, Guo J
Pharmaceuticals (2025) Vol. 18, Iss. 4, pp. 507-507
Open Access
An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infection
Atish Mukherji, Frank Jühling, Yogy Simanjuntak, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Phase 3 validation of PAaM for hepatocellular carcinoma risk stratification in cirrhosis
Naoto Fujiwara, Camden Lopez, Tracey L. Marsh, et al.
Gastroenterology (2024)
Closed Access | Times Cited: 3
Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction
Kuo Du, David S. Umbaugh, Liuyang Wang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Serum α-SMA is a potential noninvasive biomarker of liver fibrosis
Irina Cardoso-Lezama, Erika Ramos‐Tovar, Jaime Arellanes‐Robledo, et al.
Toxicology Mechanisms and Methods (2023) Vol. 34, Iss. 1, pp. 13-19
Closed Access | Times Cited: 8
A thioacetamide-induced liver fibrosis model for pre-clinical studies in microminipig
Kotaro Nishi, Hiroshi Yagi, Mana Ohtomo, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy
Kenneth K. Tanabe, David M. Zahrieh, Carrie Strand, et al.
Gastro Hep Advances (2024) Vol. 3, Iss. 3, pp. 426-439
Open Access | Times Cited: 3
Clinico‐histological and molecular features of hepatocellular carcinoma from nonalcoholic fatty liver disease
Naoto Fujiwara, Hayato Nakagawa
Cancer Science (2023) Vol. 114, Iss. 10, pp. 3825-3833
Open Access | Times Cited: 6
A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials
Shenglong Zhu, Zhiming Wu, Wenxin Wang, et al.
Journal of Endocrinological Investigation (2023) Vol. 47, Iss. 4, pp. 761-776
Closed Access | Times Cited: 6
Sample size calculation for a NanoString GeoMx spatial transcriptomics experiment to study predictors of fibrosis progression in non-alcoholic fatty liver disease
Maria Ryaboshapkina, Vian Azzu
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Inhibition of FGFR2 Signaling by Cynaroside Attenuates Liver Fibrosis
Qilin Meng, Lin Luo, Minghua Lei, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 548-548
Open Access | Times Cited: 4
A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease
Maria Jiménez Ramos, Timothy J. Kendall, Ignat Drozdov, et al.
Annals of Hepatology (2023) Vol. 29, Iss. 2, pp. 101278-101278
Open Access | Times Cited: 4
Carfilzomib shows therapeutic potential for reduction of liver fibrosis by targeting hepatic stellate cell activation
Ayana Fujiwara, Keisuke Takemura, Anna Tanaka, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Molecular mechanisms behind the inhibitory effects of ginsenoside Rg3 on hepatic fibrosis: a review
Zhao-feng Tian, Rui‐yi Hu, Zi Wang, et al.
Archives of Toxicology (2024)
Closed Access | Times Cited: 1
Origin of CAFs in colorectal cancer
Eleni Kotsiliti
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 2, pp. 79-79
Closed Access | Times Cited: 7
Hepatocellular Carcinoma Chemoprevention with Generic Agents
Fahmida Rasha, Subhojit Paul, Tracey G. Simon, et al.
Seminars in Liver Disease (2022) Vol. 42, Iss. 04, pp. 501-513
Open Access | Times Cited: 7
Emerging Roles of Spatial Transcriptomics in Liver Research
Naoto Fujiwara, Genki Kimura, Hayato Nakagawa
Seminars in Liver Disease (2024) Vol. 44, Iss. 02, pp. 115-132
Closed Access
An Integrated Genome-Metabolome-Mendelian Randomization Identifies Predictive Transcription Gene Signature of Liver Fibrosis
Xiaoyan Wang, Lin Zhang, Yu Hao Chang, et al.
(2024)
Closed Access
Carfilzomib Shows Therapeutic Potential for Reduction of Liver Fibrosis by Targeting Hepatic Stellate Cell Activation
Ayana Fujiwara, Keisuke Takemura, Anna Tanaka, et al.
Research Square (Research Square) (2024)
Open Access
Page 1 - Next Page

Scroll to top